XML 16 R5.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Series A Warrants
Series C Warrants
March 2025 Pre Funded Warrants
March 2025 Common Warrants
Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Series A Warrants
Additional Paid-in Capital
Series C Warrants
Additional Paid-in Capital
March 2025 Pre Funded Warrants
Additional Paid-in Capital
March 2025 Common Warrants
Accumulated Deficit
Beginning balance at Dec. 31, 2024 $ (5,998)           $ 85 $ 1,233,716         $ (1,239,799)
Beginning balance (in shares) at Dec. 31, 2024             8,487,818            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation 1,164             1,164          
Issuance of stock (in shares)             1,974,432            
Issuance of stock 2,222           $ 20 2,202          
Issuance of pre-funded warrants       $ 2,447 $ 4,174           $ 2,447 $ 4,174  
Net loss (10,616)                       (10,616)
Ending balance at Mar. 31, 2025 $ (6,607)           $ 105 1,243,703         (1,250,415)
Ending balance (in shares) at Mar. 31, 2025             10,462,250            
Beginning balance (in shares) at Dec. 31, 2025 0         0              
Beginning balance at Dec. 31, 2025 $ 5,462         $ 0 $ 129 1,252,714         (1,247,381)
Beginning balance (in shares) at Dec. 31, 2025 12,928,853           12,928,853            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation $ 575             575          
Issuance of stock (in shares)           20,195              
Issuance of stock 0         $ 2,261   0          
Conversion of preferred stock to common stock and pre-funded warrants upon shareholder approval (in shares)           (20,195) 26,243,754            
Conversion of convertible preferred stock to common stock and pre-funded warrants upon shareholder approval 2,261         $ (2,261) $ 262 1,999          
Reclassification of Common Warrants liability to equity   $ 16,705 $ 11,894           $ 16,705 $ 11,894      
Issuance of common stock under employee benefit plans, net of shares received to settle minimum tax obligation for vesting of restricted stock units (in shares)             42,086            
Issuance of common stock under employee benefit plans, net of shares received to settle minimum tax obligation for vesting of restricted stock units 1           $ 1            
Exercise of pre-funded warrants (in shares)             764,000            
Exercise of prefunded warrants 8           $ 8            
Net loss $ (24,199)                       (24,199)
Ending balance (in shares) at Mar. 31, 2026 0         0              
Ending balance at Mar. 31, 2026 $ 12,707         $ 0 $ 400 $ 1,283,887         $ (1,271,580)
Ending balance (in shares) at Mar. 31, 2026 39,978,693           39,978,693